Compare TSEM & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSEM | MDGL |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.1B |
| IPO Year | 1996 | 2005 |
| Metric | TSEM | MDGL |
|---|---|---|
| Price | $220.81 | $518.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $161.75 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.5M | 261.6K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $19.21 | $58.39 |
| Revenue Next Year | $26.62 | $48.55 |
| P/E Ratio | $66.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.43 | $265.00 |
| 52 Week High | $228.73 | $615.00 |
| Indicator | TSEM | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 53.02 |
| Support Level | $111.97 | $503.93 |
| Resistance Level | $228.73 | $539.17 |
| Average True Range (ATR) | 14.15 | 15.73 |
| MACD | -2.90 | -3.53 |
| Stochastic Oscillator | 82.64 | 38.62 |
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs), based on the design specifications of customers. The company's line of integrated circuits is incorporated into a range of products and markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.